QLY Biotech Group Corp.
LQLY
$1.00
-$0.06-5.66%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 194.90% | -39.94% | -56.07% | -64.58% | -69.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.04% | -42.47% | -57.91% | -60.19% | -64.67% |
| Operating Income | -301.39% | 34.59% | 52.20% | 72.73% | 77.29% |
| Income Before Tax | -301.39% | 34.59% | 52.20% | 72.73% | 77.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -301.39% | 34.59% | 52.20% | 72.73% | 77.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -301.39% | 34.59% | 52.20% | 72.73% | 77.29% |
| EBIT | -301.39% | 34.59% | 52.20% | 72.73% | 77.29% |
| EBITDA | -357.14% | 35.54% | 54.48% | 75.16% | 79.81% |
| EPS Basic | -289.47% | 34.67% | 52.63% | 73.81% | 77.38% |
| Normalized Basic EPS | -291.67% | 34.04% | 51.06% | 73.08% | 76.92% |
| EPS Diluted | -289.47% | 34.67% | 52.63% | 73.81% | 77.38% |
| Normalized Diluted EPS | -291.67% | 34.04% | 51.06% | 73.08% | 76.92% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 4.60% | 11.28% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 4.60% | 11.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |